Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial

Status Not yet recruiting

Clinical Trial Summary

To compare short-term clinical outcomes of primary PCI between the ostial LAD-AMI and the non-ostial LAD-AMI. The primary endpoint was the major cardiovascular events (MACE) defined as being the composite of cardiac death, AMI, stent thrombosis

Clinical Trial Description

Current guidelines recommend percutaneous coronary intervention (PCI) for most patients with ST segment elevation acute myocardial infarction (STEMI) or with non ST segment elevation acute coronary syndrome (NSTEACS) (1), (2). In STEMI patients, PCI is advised in all patients in the first 12 hours after onset of symptoms, the earlier the better (1).

Coronary revascularization does not always lead to coronary reperfusion. The development of devices and procedure has improved clinical outcomes of percutaneous coronary intervention (PCI) to the culprit of acute myocardial infarction (AMI) (3-5).

However, proximal left anterior descending artery (LAD)-AMI has still been associated with high morbidity and mortality because of the broad ischemic area (6, 7). In fact, clinical outcomes were significantly worse in the proximal LAD-AMI as compared with the mid LAD-AMI.5) Moreover, the proximal LAD disease in stable angina was closely associated with early revascularization following optimal medical therapy (8). Therefore, clinical guidelines regarding coronary revascularization have discriminated the proximal LAD disease from other LAD diseases (9).

In terms of coronary revascularization, the ostial LAD disease requires special attention in the proximal LAD disease, because percutaneous coronary interventions (PCI) can be more complex in the ostial LAD disease than in the non-ostial proximal LAD disease (10) even in the setting of AMI, left-main-trunk (LMT)-to-LAD crossover stenting was frequently required in the ostial LAD disease (11). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04104048
Study type	Observational
Source	Assiut University
Contact	yehia taha, professor
Phone	01223971269
Email	ytkishk2002@yahoo.com
Status	Not yet recruiting
Phase
Start date	September 2020
Completion date	October 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04451967` - Acute Myocardial Infarction Study in Northeastern China
Completed	`NCT05974397` - Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Not yet recruiting	`NCT04072081` - Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions	N/A
Recruiting	`NCT03940443` - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting	`NCT03707626` - Collateral Circulation to LAD and Wellens Sign
Completed	`NCT02669810` - EXCELLENT (EXpanded CELL ENdocardiac Transplantation)	Phase 2
Active, not recruiting	`NCT02915107` - The SORT OUT IX STEMI OCT Trial	N/A
Completed	`NCT02896543` - The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction	N/A
Completed	`NCT02531165` - Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	N/A
Completed	`NCT02490969` - Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19	N/A
Withdrawn	`NCT01901471` - Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock	Phase 2
Completed	`NCT02312336` - A Pilot Study of Transcoronary Myocardial Cooling	N/A
Recruiting	`NCT02071342` - Study of ABSORB Stent in Acute Myocardial Infarction	N/A
Terminated	`NCT01972126` - MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction	N/A
Completed	`NCT02070913` - COOL-AMI EU Case Series Clinical Study
Completed	`NCT01887080` - Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program	N/A
Withdrawn	`NCT01678339` - Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients	N/A
Completed	`NCT01216995` - Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)	Phase 2
Completed	`NCT01673893` - ClearWay Rx Readmission Registry
Completed	`NCT01325116` - Delayed Educational Reminders in Acute Myocardial Infarction (MI)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms